would like to know about allogeneic cell therapy vs bispecific across hematology oncology and autoimmune disease, from efficacy and potential market adoption , simply which one will eventually rule the space 🙏
I've written about this in a few different past posts, but generally for auto-immune I think bsAbs will likely fair better commercially than cell therapy. Better bang for your buck for most common AID (at least so far). No LD needed either. I'm intrigued by where in vivo CARs can go in this space.
For heme/onc I think both allo' and bsAbs will continue to play a role. Auto CAR-T is hitting capacity right now and the companies need to push to increase access beyond centers of excellence. Allo' can piggy back off of that center-expansion and may be a better fit for patients who can't wait for treatment. I'm somewhat worried about the infection rates seen with HD Allo' due to the heavier LD. BsAbs will be a strong option as bridging therapy and for community hospitals where CAR-T would require a referral-out.
would like to know about allogeneic cell therapy vs bispecific across hematology oncology and autoimmune disease, from efficacy and potential market adoption , simply which one will eventually rule the space 🙏
I've written about this in a few different past posts, but generally for auto-immune I think bsAbs will likely fair better commercially than cell therapy. Better bang for your buck for most common AID (at least so far). No LD needed either. I'm intrigued by where in vivo CARs can go in this space.
For heme/onc I think both allo' and bsAbs will continue to play a role. Auto CAR-T is hitting capacity right now and the companies need to push to increase access beyond centers of excellence. Allo' can piggy back off of that center-expansion and may be a better fit for patients who can't wait for treatment. I'm somewhat worried about the infection rates seen with HD Allo' due to the heavier LD. BsAbs will be a strong option as bridging therapy and for community hospitals where CAR-T would require a referral-out.